文献速递母胎医学

对存在苯丙酮尿症风险的妊娠采用全面定量cSMART法检测PAH基因突变的非侵入性胎儿基因分型:一项临床可行性研究

Noninvasive fetal genotyping in pregnancies at risk for PKU using a comprehensive quantitative cSMART assay for PAH gene mutations: a clinical feasibility study.
PubMed 文献 · BJOG · 2019-08-16

该研究在上海新华医院和湖南家辉遗传医院对33对已生育苯丙酮尿症(PKU)患儿的夫妇进行盲法非侵入性产前检测(NIPT),采用PAH基因特异性cSMART法,并与侵入性产前诊断(IPD)金标准比较。结果显示33例胎儿中32例(96.97%)基因分型准确,NIPT灵敏度为100.00%(95%CI 59.04-100.00%),特异度为96.15%(95%CI 80.36-99.90%)。作者认为该检测在已知双方或一方家族有PKU史的高危和低危妊娠快速筛查中具有临床实用价值。

要点

  • 33例高危胎儿中NIPT与IPD结果一致32例(96.97%)。
  • NIPT灵敏度100.00%(95%CI 59.04-100.00%),特异度96.15%(95%CI 80.36-99.90%)。
  • 作者提出该cSMART法可用于已知PKU家族史妊娠的快速筛查。

核心结论

  • 新型cSMART法在正确判定胎儿基因型方面表现出高准确性。
  • 作者提出该检测对已知双方或一方家族有PKU史的高危和低危妊娠快速筛查具有临床实用价值。

研究设计与样本

  • 对存在PKU高风险的妊娠进行盲法NIPT分析。
  • 研究地点为中国上海新华医院和湖南家辉遗传医院。
  • 研究人群为已生育一名PKU患儿的夫妇33对。
  • 采用Sanger测序对夫妇及患儿进行PAH致病突变的三人组检测。
  • 在第二次妊娠中采用侵入性产前诊断(IPD)确定胎儿基因型。

主要发现

  • 与金标准IPD结果比较,33例胎儿中32例(96.97%)经NIPT准确基因分型。
  • NIPT检测的灵敏度为100.00%(95%CI 59.04-100.00%)。
  • NIPT检测的特异度为96.15%(95%CI 80.36-99.90%)。

关键数值与推荐

  • NIPT灵敏度100.00%(95%CI 59.04-100.00%),特异度96.15%(95%CI 80.36-99.90%)。
  • 33例胎儿中NIPT与IPD基因分型一致32例(96.97%)。

临床怎么用

  • 作者提出该检测对已知双方或一方家族有PKU史的高危和低危妊娠快速筛查具有临床实用价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the diagnostic performance of a novel circulating single molecule amplification and re-sequencing technology (cSMART) method for noninvasive prenatal testing (NIPT) of Phenylketonuria (PKU). DESIGN: Blinded NIPT analysis of pregnancies at high risk for PKU. SETTING: Shanghai Xinhua Hospital and Hunan Jiahui Genetics Hospital, China. POPULATION: Couples (n = 33) with a child diagnosed with PKU. METHODS: Trio testing for pathogenic PAH mutations was performed by Sanger sequencing. In second pregnancies, invasive prenatal diagnosis (IPD) was used to determine fetal genotypes. NIPT was performed using a PAH gene-specific cSMART assay. Based on the plasma DNA mutation ratio relative to the fetal DNA fraction, fetal genotypes were assigned using a maximum-likelihood algorithm. MAIN OUTCOME MEASURES: Concordance of fetal genotyping results between IPD and NIPT, and the sensitivity and specificity of the NIPT assay. RESULTS: Compared with gold standard IPD results, 32 of 33 fetuses (96.97%) were accurately genotyped by NIPT. The sensitivity and specificity of the NIPT assay was 100.00% (95% CI 59.04-100.00%) and 96.15% (95% CI 80.36-99.90%), respectively. CONCLUSIONS: The novel cSMART assay demonstrated high accuracy for correctly calling fetal genotypes. We propose that this test has useful clinical utility for the rapid screening of high-risk and low-risk pregnancies with a known history of PKU on one or both sides of the family. TWEETABLE ABSTRACT: NIPT of couples at high risk for PKU using a full-coverage cSMART PAH gene test.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Lv W, Li Z, Wei X, et al. Noninvasive fetal genotyping in pregnancies at risk for PKU using a comprehensive quantitative cSMART assay for PAH gene mutations: a clinical feasibility study. BJOG. 2019. PMID: 31295388. doi:10.1111/1471-0528.15869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。